Yu-Long Xia

In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more.

It is argued that the major limitations of CAR-T therapy in solid tumors arise from a complex interplay between biological barriers and engineering constraints, and future advances will likely depend less on improving gene delivery and more on establishing mechanisms that support CAR-T infiltration, expansion, and pers...